Traders should await the actual earnings release and call for material data. No trading action is warranted based on this announcement alone.
CTMX drugs
CTMX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 4 $5.07entry
- T+1 · 9mo ago −5.92%α −5.34% · $4.77
- T+5 · 8mo ago −3.75%α −2.41% · $4.88
- T+20 · 8mo ago −10.06%α −5.64% · $4.56
- T+60 · 6mo ago −26.82%α −36.91% · $3.71
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CytomX Therapeutics announced it will report full year 2025 financial results on March 16, 2026, before markets open, followed by a conference call. The press release contains no financial data, forward-looking results, or operational updates beyond the announcement of the earnings event.
Key Facts
- CytomX Therapeutics (CTMX) will report full year 2025 financial results on March 16, 2026, before market open.
- Company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT on the same day.
- No financial results, guidance, or material operational updates were disclosed in this press release.
- The release serves solely as a scheduling announcement for upcoming earnings.
Financial Impact
No financial data disclosed
Risk Factors
- Earnings could miss expectations given lack of pre-announcement or positive signaling.
- Biotech stocks like CTMX often experience volatility around earnings, especially with no forward guidance provided.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249296 |
Track record
10 reports on CTMX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago SC 13G Neutral 2/10 Entry $1.98 Now $1.99 +0.25% settles Feb 8
- Nov 5, 202611d ago Press Release Bearish 5/10 No price data
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $2.19 Now $1.99 −9.36% settles Feb 4
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $2.36 Now $1.99 −15.89% settles Jan 26
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $2.94 Now $1.99 −32.48% settles Dec 16
- Jun 22, 202621w ago 8-K Neutral 3/10 Entry $3.15 to $2.77 Now $1.99 −36.98% ▼ −12.22% −15.47% vs SPY
- Mar 17, 202634w ago Press Release Neutral 6/10 Entry $4.40 to $2.98 Now $1.99 −54.89% ▼ −32.27% −43.80% vs SPY
- Mar 16, 202635w ago Press Release Bearish 7/10 Entry $5.45 to $2.98 Now $1.99 +63.58% ▲ +45.32% +55.18% vs SPY
- Mar 16, 202635w ago Press Release Mixed 6/10 Entry $6.75 to $2.94 Now $1.99 −70.59% ▼ −56.44% −66.93% vs SPY
- Mar 4, 202636w ago Press Release Neutral 3/10 Viewing Entry $5.07 to $3.71 Now $1.99 −60.85% ▼ −26.82% −36.91% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers